OMDA Stock Forecast & Price Target

Omada Health is supported by a large and underpenetrated cardiometabolic addressable market, with about 188 million insured U.S. adults having treatable conditions, while it currently serves only about 1.1 million active members across 25 million covered lives, leaving substantial room for enrollment and cross-sell growth. Its Buy outlook is reinforced by improving profitability economics: management lifted long-term gross margin expectations to 80% from 70% and EBITDA margins to 30% from 20%, aided by AI-enabled automation, better coach productivity, lower cost of revenue per member, and a richer mix of higher-ARPU offerings such as GLP-1 prescribing and cholesterol care. The business also benefits from sticky B2B2C distribution through large PBMs, health plans, and employers, with 33%+ of contracts already multi-product, roughly 90% customer retention, and 38% revenue growth in FY24, suggesting a durable recurring-revenue model with meaningful operating leverage.

Omada Health is vulnerable because its growth still depends on persuading members to enroll and stay active in digital programs, a challenge that has long constrained employer wellness adoption despite net revenue retention of 128%. Its fees are tied to the number of covered individuals enrolled each month, so weak consumer engagement, declining covered lives, or lower utilization can quickly pressure revenue and limit operating leverage. Even with expected 30% revenue growth this year and 2027E EBITDA growth of +55% y/y, the lower margin profile versus peers and concentration risk with partners like Cigna make the stock fundamentally less attractive.